RIMADYL by Roche is clinical pharmacology carprofen is a non-narcotic, non-steroidal anti-inflammatory agent with characteristic analgesic and antipyretic activity approximately equipotent to indomethacin in animal models. First approved in 1987.
Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
RIMADYL (carprofen) is a non-steroidal anti-inflammatory drug (NSAID) that works by selectively inhibiting COX-2 cyclooxygenase to reduce inflammation, pain, and fever. It is primarily used in veterinary medicine for dogs to manage inflammatory conditions and pain. Carprofen demonstrates rapid oral absorption with peak plasma concentrations achieved within 1–3 hours and a terminal half-life of approximately 8 hours.
Product is approaching loss of exclusivity after 35+ years on market; brand team likely focused on lifecycle management and transition planning rather than growth initiatives.
CLINICAL PHARMACOLOGY Carprofen is a non-narcotic, non-steroidal anti-inflammatory agent with characteristic analgesic and antipyretic activity approximately equipotent to indomethacin in animal models. The mechanism of action of carprofen, like that of other NSAIDs, is believed to be associated…
Worked on RIMADYL at Roche? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
RIMADYL offers limited career growth opportunities given its mature, LOE-approaching status and minimal linked job activity (zero positions identified). Roles on this product focus primarily on defensive commercial management, channel maintenance, and transition planning rather than innovation or expansion.